Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1JGDM)

Drug Name
Lpc-Ether Drug Info
Synonyms
LPC-ETHER; 1-O-OCTADECYL-SN-GLYCERO-3-PHOSPHOCHOLINE; LPE; 1-Octadecyl-sn-glycero-3-phosphocholine; AC1L9K7A; CBiol_001783; SCHEMBL11889677; Bio1_000558; Bio1_000069; Bio1_001047; ZINC8860508; DB03633; O-(1-O-Octadecyl-L-glycero-3-phospho)choline; SR-01000946544; SR-01000946544-1; (4S,7R)-4,7-dihydroxy-N,N,N-trimethyl-3,5,9-trioxa-4-phosphaheptacosan-1-aminium 4-oxide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
446876
TTD Drug ID
DM1JGDM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Phospholipase A2 (PLA2G1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [1]
Miltefosine DMND304 Chronic urticaria Approved [2]
Clocortolone DM9ZMQH Exanthem Approved [3]
Clobetasol DMUXP52 Rosacea ED90.0 Approved [4]
Diflorasone DMI9PRJ Exanthem Approved [5]
AllerB DM78DOT Allergy 4A80-4A85 Phase 2b [6]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [7]
MANOALIDE DMB4A8I Arthritis FA20 Phase 2 [8]
MRX-4 DMQZWYE Allergic rhinitis CA08.0 Phase 2 [9]
MRX-6 DMLVQKF Contact dermatitis EK0Z Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phospholipase A2 (PLA2G1B) TT9V5JH PA21B_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
3 Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
4 Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
5 Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
6 Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
7 Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
8 Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
9 Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
10 A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.